MALVERN, Pa., May 12, 2014 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a clinical stage specialty pharmaceutical company developing non-opioid therapeutics for the treatment of pain, initially for acute pain following surgery, today reported financial results for the first quarter ended March 31, 2014. “Following our successful initial public offering in March 2014, Recro Pharma is well positioned to advance our lead candidate Dex-IN, in trials for the treatment of post-operative pain,” said Gerri Henwood, Recro Pharma’s President and Chief Executive Officer. “We look forward to beginning enrollment of our Dex-IN Phase IIb bunionectomy trial in the second quarter 2014. Dex-IN is a non-opioid therapeutic that, if approved, would be the first and only acute pain drug in its class and could provide an attractive alternative to commonly prescribed opioids for acute pain. We expect to have top line data from this trial by the end of 2014.”
Help employers find you! Check out all the jobs and post your resume.
